2025. Concurrent EGFR and KRAS mutations in non-small cell lung cancer: Challenging the paradigm of linear targeted therapy. Journal of Current Biomedical Reports. 6, 2 (Jun. 2025), 45–46. DOI:https://doi.org/10.61882/jcbior.6.2.299.